MBX Biosciences, Inc. SEC filings MBX
MBX Biosciences, Inc. has 232 filings in SEC EDGAR's recent list, going back to May 10, 2019. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 22, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 22, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 27, 2026 | Aug 27, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 13, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 12, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 11, 2026 | May 11, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 12, 2026 | Mar 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 9, 2026 | Mar 9, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Feb 27, 2026 | Feb 24, 2026 |
| 8-K |
Current report
Other events
|
Feb 5, 2026 | Feb 4, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 22, 2026 | Jan 20, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Jan 12, 2026 | Jan 11, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Nov 6, 2025 | Oct 31, 2025 |
| 8-K |
Current report
Material agreement
|
Sep 26, 2025 | Sep 24, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 22, 2025 | Sep 22, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 4, 2025 | Sep 4, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 16, 2025 | Jun 16, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 9, 2025 | Jun 9, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 6, 2025 | Jun 5, 2025 |
| 8-K |
Current report
Results of operations
|
May 12, 2025 | May 12, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 7, 2025 | Apr 7, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 17, 2025 | Mar 17, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Jan 7, 2025 | Jan 7, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 16, 2024 | Sep 16, 2024 |
Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MBX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Carmel, IN
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1776111
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.